A Pharmacokinetic Study of Zavegepant Nasal Spray in Healthy Adults Comparing Conventional Venous Blood Sampling With Patient‐Centric Microsampling
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70199 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Mohamed H Shahin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., Groton, Connecticut, USA. Hauptthemen laut MEDLINE: Blood Specimen Collection. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
This Phase 1, non‐randomized, open‐label, 2‐period study compared the pharmacokinetics (PK) of zavegepant nasal spray, using samples collected via patient‐centric microsampling (PCS) devices, with those collected through venous phlebotomy (NCT05948085). Fourteen healthy participants received a single intranasal dose of 10 mg zavegepant on Days 1 and 2. Blood samples for PK analysis were collected at 0.5, 1, 2, 4, 8, and 12 h post dose on Day 1 using the Tasso‐Plus device ( n = 7; produces serum samples), Tasso‐M20 ( n = 7; produces dried blood samples), and venous phlebotomy ( n = 14). PK parameters were calculated using non‐compartmental methods. Natural log‐transformed areas under the plasma/serum concentration‐time profile from time zero to the time of the last quantifiable concentration (AUC last ) and maximum serum/plasma concentration (C max ) of zavegepant were analyzed using a mixed‐effects model, with blood collection as a fixed effect and participant as a random effect. Of the two PCS devices assessed, the results of the Tasso‐Plus device showed successful bridging with venous phlebotomy sampling. For Tasso‐Plus versus venous phlebotomy, 39 of 41 (95.1%) data pairs met concentration correlation criteria (difference within 20% of the mean), median zavegepant concentration‐time profiles were comparable, and 90% confidence intervals for geometric mean ratios for AUC last and C max were wholly within the range of bioequivalence acceptance (80%–125%). The results of this study confirm that it is feasible to use serum derived from Tasso‐Plus collection of whole capillary blood as a reliable PCS approach for PK analysis of zavegepant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer Inc., Groton, Connecticut, USA.
- Pfizer Inc., Lake Forest, Illinois, USA.
- Pfizer Inc., La Jolla, California, USA.
- Pfizer, Moscow, Russia.
- Pfizer Inc., Collegeville, Pennsylvania, USA.
ORCID-Profile: Robert Fountaine
Zitieren
APA
Shahin, M. H., Fisniku, O., Ding, D., Wan, K., Dubrovin, S., Matschke, K., Kavetska, O., Fountaine, R., & Liu, J. (2025). A Pharmacokinetic Study of Zavegepant Nasal Spray in Healthy Adults Comparing Conventional Venous Blood Sampling With Patient‐Centric Microsampling. Clinical and Translational Science. https://doi.org/10.1111/cts.70199
Vancouver
Shahin MH, Fisniku O, Ding D, Wan K, Dubrovin S, Matschke K, et al. A Pharmacokinetic Study of Zavegepant Nasal Spray in Healthy Adults Comparing Conventional Venous Blood Sampling With Patient‐Centric Microsampling. Clinical and Translational Science. 2025. doi:10.1111/cts.70199
BibTeX
@article{Shahin2025,
author = {Shahin, Mohamed H and Fisniku, Ogert and Ding, Ding and Wan, Katty and Dubrovin, Sergey and Matschke, Kyle and Kavetska, Olga and Fountaine, Robert and Liu, Jing},
title = {A Pharmacokinetic Study of Zavegepant Nasal Spray in Healthy Adults Comparing Conventional Venous Blood Sampling With Patient‐Centric Microsampling},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70199}
}
EUVIMED